Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review

Anti-VEGF (vascular endothelial growth factor) therapy with the monoclonal antibody bevacizumab can cause gastrointestinal (GI) perforations. In recent years it became apparent that GI perforations also occur during treatment with antiangiogenic tyrosine kinase inhibitors (TKIs). It is of clinical i...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Walraven, Maudy, Witteveen, Petronella O., Lolkema, Martijn P. J., van Hillegersberg, R., Voest, Emile E., Verheul, H. M. W.
Format: Artigo
Jezik:Inglês
Izdano: Springer Netherlands 2010
Teme:
Original Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3102838/
https://ncbi.nlm.nih.gov/pubmed/21188500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10456-010-9197-6
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki